Introduced in House | Passed House | Introduced in Senate | Passed Senate | To President | Became Law |
02/13/2020 |
Transparency in Prescription Drug Advertising Act
Picture | Name | From | Date | Type |
---|---|---|---|---|
Sharice Davids | D-KS | 02/13/2020 | Sponsor | |
Elissa Slotkin | D-MI | 02/13/2020 | Cosponsor | |
Ed Perlmutter | D-CO | 05/01/2020 | Cosponsor | |
Abby Finkenauer | D-IA | 02/13/2020 | Cosponsor |
Date | Branch | Action |
---|---|---|
02/13/2020 | President | Referred to the House Committee on Energy and Commerce.Action By: House of Representatives |
02/13/2020 | President | Introduced in HouseAction By: House of Representatives |
Summary |
---|
There is one summary for H.R.5894. View summaries Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority. |
Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority. |